latest news releases from the newsroom
Polydex Pharmaceuticals Limited
Polydex Pharmaceuticals Receives Staff Deficiency Letter from Nasdaq
TORONTO, Jan. 22, 2008 (PRIME NEWSWIRE) -- Polydex Pharmaceuticals Limited (Nasdaq:POLXF) announced today that on January 18, 2008, it received a Nasdaq Staff Deficiency Letter from The Nasdaq Stock Market notifying it that the Company's bid price per share for its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days. As a result, Polydex no longer meets the requirements of Marketplace Rule 4310(c)(4) for continued listing on The Nasdaq Capital Market and has 180 calendar days, or until July 14, 2008, to regain compliance. During this 180-day period, Polydex shares will continue to trade on The Nasdaq Capital Market.
Directors Guild of America
DGA Sets Host and Presenters for 60th Annual DGA Awards Dinner
LOS ANGELES, Jan. 22, 2008 (PRIME NEWSWIRE) -- DGA President Michael Apted announced today that Carl Reiner will return as host for the 60th Annual Directors Guild of America Awards. This year will mark the 21st time Reiner has hosted the DGA Awards, which will take place on Saturday, January 26, 2008 at the Hyatt Regency Century Plaza in Los Angeles.
Nabi Biopharmaceuticals Initiates New Strategic Alternatives Process
ROCKVILLE, Md., Jan. 22, 2008 (PRIME NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced today that its Board of Directors has authorized the exploration of the full range of strategic alternatives available to the company in order to further enhance shareholder value. This strategic alternatives process will focus on, but is not limited to, a sale or merger of the company. Nabi has engaged Banc of America Securities LLC as financial advisor for this strategic process.
Port of Houston Authority
PHA Commission Approves $74 Million for Next Bayport Wharf
HOUSTON, Jan. 22, 2008 (PRIME NEWSWIRE) -- The Port Commission of The Port of Houston Authority (PHA) approved advertising for the construction of an additional wharf at the Bayport Terminal complex, a contract estimated to value up to $74 million. Additionally, the Commission approved $9 million for the purchase of unleaded gasoline and Texas low-emission diesel fuel (TXLED), and H. Thomas Kornegay, PHA executive director, gave PHA's year-end review, highlighting another record-breaking year, at the regular January 22 meeting.
Nabi Biopharmaceuticals Names Dr. Raafat E.F. Fahim as President and Chief Executive Officer
ROCKVILLE, Md., Jan. 22, 2008 (PRIME NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that the company's Board of Directors has named Raafat E.F. Fahim, Ph.D. as President and Chief Executive Officer. Dr. Fahim, who also joins the Board as a director, succeeds Leslie Hudson, Ph.D., who had served as Interim President and Chief Executive Officer since February 2007. Dr. Hudson will remain on the Board of Directors.